Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 1;77(1):6-9.
doi: 10.1002/hep.32627. Epub 2022 Jul 10.

Imaging for better responses to immunotherapy in hepatocellular carcinoma

Katherine E Lindblad  1   2   3   4 , Amaia Lujambio  1   2   3   4
Affiliations
Editorial

Imaging for better responses to immunotherapy in hepatocellular carcinoma

Katherine E Lindblad et al. Hepatology. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Pipeline for selection of HCC patients with steatosis and treatment with combination immunotherapy. MR, magnetic resonance; CTL, cytotoxic T cells; TME, tumor microenvironment.
See this image and copyright information in PMC

Comment on

References

    1. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–62. Epub 2019/04/11. doi: 10.1056/NEJMra1713263. - DOI - PubMed
    1. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A, Global Nonalcoholic Steatohepatitis C. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–55 e3. Epub 2018/06/17. doi: 10.1016/j.cgh.2018.05.057. - DOI - PubMed
    1. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. Epub 2018/08/01. doi: 10.1038/s41571-018-0073-4. - DOI - PubMed
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. Epub 2008/07/25. doi: 10.1056/NEJMoa0708857. - DOI - PubMed
    1. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502. Epub 2017/04/25. doi: 10.1016/S0140-6736(17)31046-2. - DOI - PMC - PubMed

MeSH terms